Leukemia Clinical Trials in Detroit

Showing 581-600 of 782 trials

Immunogenicity of PCV-7 Vaccine in VLBW Infants

NCT00273325

Premature infants are at a high risk for pneumonia. The PCV-7 vaccine effectively prevents the invasive disease from Streptococcus pneumoniae in full-term infants, but was not thoroughly studied in premature infants. This study evaluated the effectiveness and safety of the vaccine given in routine practice to very low birth weight infants, looking at blood antibody levels 4-6 weeks after the final vaccine dose, and adverse events, survival, infections, and neurodevelopmental outcomes at 18-22 months corrected age.

Pneumococcal InfectionsStreptococcus PneumoniaeInfant, Newborn+3 more

NICHD Neonatal Research Network368 participantsStarted Jul 2004

Birmingham, Alabama, United States • Palo Alto, California, United States • Miami, Florida, United States +7 more locations

COMPLETEDPHASE2/PHASE3< 1 mile

Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome

NCT01203358

The purpose of this study is to compare the efficacy of two surfactants, Exosurf Neonatal (Burroughs Wellcome Co.) and Survanta (Ross Laboratories), for the treatment of neonatal respiratory distress syndrome.

Infant, NewbornInfant, Low Birth WeightInfant, Small for Gestational Age+2 more

NICHD Neonatal Research Network617 participantsStarted Jan 1991

Palo Alto, California, United States • New Haven, Connecticut, United States • Washington D.C., District of Columbia, United States +10 more locations

Immunogenicity of PCV-7 Vaccine in VLBW Infants

Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome

Leukemia Trials in Other Cities

Early Diagnosis of Candidiasis in Premature Infants

Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage

Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection

Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).

A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia

A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia

Other Conditions in Detroit